# Influenza Vaccine Effectiveness in Korea: A Systematic Review and Meta-Analysis of Real-World Evidence from the Past Decade

## TL;DR

This study reviews and analyzes influenza vaccine effectiveness in Korea over the past decade using real-world data.

## Contribution

It provides a comprehensive synthesis of fragmented vaccine effectiveness evidence in Korea using a systematic review and meta-analysis.

## Key findings

- Vaccine effectiveness was 23.6% in adults and 25.2% in children.
- Effectiveness against influenza A in children was 32.4%.
- Findings suggest suboptimal vaccine effectiveness compared to global estimates.

## Abstract

Background: Influenza remains a significant public health burden. Although vaccination is the most effective preventive strategy, evidence on influenza vaccine effectiveness (VE) in Korea remains fragmented. Methods: A systematic review and meta-analysis were conducted on real-world Korean influenza VE studies published from January 2016 to October 2025. Literature research was performed in PubMed, Embase, and Web of Science. Eligible studies evaluated influenza VE using real-world data sources. Pooled VE estimates were calculated using a random-effects model and stratified by age group and virus type. Results: A total of 2922 records were identified, of which nine studies met the inclusion criteria and eight were included in the meta-analysis. Eight of nine studies were conducted in hospital settings. Five studies targeted adults (including two focusing on those aged ≥ 65 years), and four targeted children. Six of the nine studies evaluated single influenza seasons, while the remaining three covered multiple seasons. Statistically significant VE was observed among adults (23.6%, 95% confidence interval [CI]: 13.8 to 32.2), children (25.2%, 95% CI: 8.2 to 39.0) and against influenza A in children (32.4%, 95% CI: 17.7 to 44.4). Conclusions: This study synthesized a decade of fragmented VE evidence in Korea. Findings suggest suboptimal effectiveness compared to global estimates, highlighting the need for further evaluation of alternative vaccine platforms, including cell-based vaccines, within Korea’s national immunization strategy.